This inventor holds 65 USPTO granted patents and 42 published patent applications and 20 EPO patents, primarily in Immunotherapy Treatments (CPC class H04W). Top assignees: China Academy of Telecommunications Technology, Eucure (Beijing) Biopharma Co., Ltd., Biocytogen Pharmaceuticals (Beijing) Co., Ltd.. Active years: 2012-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Inventors with similar research interests:
Company Filing History:
13 out of 633 
8 out of 8 
4 out of 33 
Years Active: 2012-2025
Areas of Expertise:
Title: Chen Wang: Innovator in Cancer Treatment
Introduction
Chen Wang, a prolific inventor based in Beijing, China, holds an impressive portfolio of 61 patents. His groundbreaking work primarily focuses on therapeutic interventions for cancer, positioning him at the forefront of biopharmaceutical innovation.
Latest Patents
Two of Wang's latest patents are making significant strides in cancer treatment methodologies. The first patent involves anti-PD-1 antibodies, which are crucial for targeting programmed cell death protein 1, a key regulator in immune response. This invention encompasses various antigen-binding fragments and outlines methods of treatment that could enhance patient outcomes in cancer therapies. The second patent centers around anti-CD40 antibodies, which target the TNF Receptor Superfamily Member 5. This patent also addresses the applications of these antibodies and their potential benefits in oncology.
Career Highlights
Throughout his career, Chen Wang has made substantial contributions to the field of biopharmaceuticals. He has collaborated with prominent institutions such as the China Academy of Telecommunications Technology and Eucure (Beijing) Biopharma Co., Ltd., where his innovations have driven significant advancements in cancer treatment technologies. His extensive research and development efforts have positioned these companies as leaders in the industry.
Collaborations
During his tenure, Wang has had the opportunity to collaborate with esteemed colleagues, including Yuelei Shen and Jingshu Xie. These partnerships have fostered a synergistic approach to research, enabling the exploration of novel therapeutic pathways in cancer treatment and expanding the frontiers of biomedical innovation.
Conclusion
Chen Wang stands out as a pioneering inventor whose contributions to the field of cancer treatment through his numerous patents are commendable. His dedication to advancing biopharmaceutical research not only reflects his commitment to improving patient care but also reinforces the importance of innovation in the healthcare sector. As Wang continues to explore new horizons in cancer therapy, the impact of his work is bound to resonate within both scientific communities and patient populations worldwide.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile